TMCnet News
ImmunoGen, Inc. Announces Presentations at Upcoming AACR Annual Meeting 2015ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC (News - Alert)) technology, today announced the presentations on Company and partner programs to be made at the upcoming American Association for Cancer Research (AACR) annual meeting to be held April 18-22, 2015 in Philadelphia, PA. These presentations will feature scientific data for ImmunoGen and partner ADCs as well as an array of ImmunoGen technology innovations. "The presentations on ADCs by ImmunoGen researchers and our partners at AACR this year illustrate our ongoing commitment to advancing the ADC field to achieve better therapies for people with cancer," commented Daniel Junius, President and CEO. "The topics span research in support of our IMGN853 and IMGN779 product candidates, preclinical data for five partner ADCs, and some of the findings from our research related to site-specific payload attachment to antibodies." Presentations Related to ImmunoGen, Partner ADCs
Site-specific linkage; payload molecules/antibody - benefit assessment, novel approaches
Expanding portfolio of novel payload agents
Advancing ADC screening methodologies
Additional information - including abstracts and presentation schedule - can be found at www.aacr.org About ImmunoGen, Inc. ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company's ADC technology uses tumor-targeting antibodies to deliver an ImmunoGen cell-killing agent specifically to cancer cells; the Company has also developed antibodies with anticancer activity of their own. The first product with ImmunoGen's ADC technology is Roche's Kadcyla®. ImmunoGen has three wholly owned product candidates in clinical testing with additional compounds in clinical testing through the Company's partnerships with Amgen, Bayer HealthCare, Biotest, Novartis and Sanofi. More information about ImmunoGen can be found at www.immunogen.com. Kadcyla® is a registered trademark of Genentech, a member of the Roche Group. This press release includes forward-looking statements. For these statements, ImmunoGen claims the protection of the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. It should be noted that there are risks and uncertainties related to the development of novel anticancer products, including risks related to preclinical and clinical studies, their timings and results. A review of these risks can be found in ImmunoGen's Annual Report on Form 10-K for the fiscal year ended June 30, 2014 and other reports filed with the Securities and Exchange Commission.
|